Pasquale Rescigno

Clin. Snr Lecturer/Honorary Consultant

Newcastle University

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Medical Imaging Medical Imaging professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Pasquale Rescigno is a Clinical Senior Lecturer and Honorary Consultant at Newcastle University, UK. His research focuses on urological oncology, particularly in the areas of treatment planning through digital twins, the effects of coagulation factors in prostate cancer therapy, and the prognostic indicators in metastatic renal cell carcinoma. He is actively involved in studies that explore the efficacy of immunotherapy and the management of bone health in prostate cancer patients.

Articles (10)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (4)

Jean-Philippe Theurillat

Associate Professor

Università del Salento

SWITZERLAND

View details

Wayne Phillips

Adjunct Professor

Monash Health

AUSTRALIA

View details

Marco Stellato

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

View details

Vincenza Conteduca

Associate Professor

University of Foggia

ITALY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Pasquale Rescigno

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer

Digital Twins in Urological Oncology: Precise Treatment Planning via Complex Modeling.

Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study.

Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab.

A red blood cell-based score in the prognostication of patients with metastatic RCC of the Meet-URO 15 study.

Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy.

Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study.

Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 study.

International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study).

Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies.

Collaborators (4)

Jean-Philippe Theurillat

Wayne Phillips

Marco Stellato

Vincenza Conteduca

Make your next move.